Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13RÎ±2 CAR T Cell Program for Glioblastoma), and others.

Employees

Sector

Pharmaceuticals

Calendar

11-13 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
09/11/26	$1.990	+7.57%	289,754
06/11/26	$1.850	+0.54%	129,816
05/11/26	$1.840	-6.60%	307,429
04/11/26	$1.970	+1.55%	124,384
03/11/26	$1.940	+0.52%	100,709

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.990USD

Average target price

5.000USD

Spread / Average Target

+151.26%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Fortress Biotech, Inc.

Revisions to estimates

Quarterly earnings, Rate of surprise

Rate of surprise - EPS - Quarterly - Fortress Biotech, Inc.

Company calendar

Market Closed - Nasdaq 00:00:00 10/11/2026 +03			5-day change	1st Jan Change
1.990 ^USD	+7.57%		+3.11%	-45.63%

10-01	Fortress Biotech, Inc. Repays Remaining $15 Million Outstanding Principal Under Oaktree Agreement	CI
08-13	Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	66.37M 59.24M 54.51M 49.47M 93.76M 6.22B 96.09M 652M 260M 3.33B 249M 244M 10.49B	P/E 2026 *	0.78x	P/E 2027 *	-1.99x
Enterprise Value	66.37M 59.24M 54.51M 49.47M 93.76M 6.22B 96.09M 652M 260M 3.33B 249M 244M 10.49B	EV / Sales 2026 *	0.84x	EV / Sales 2027 *	0.59x
Free-Float	76.1%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	FBIO	Delayed
CBOE	FBIO	Real-time

10-01	Fortress Biotech, Inc. Repays Remaining $15 Million Outstanding Principal Under Oaktree Agreement	CI
08-13	Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-13	Fortress Biotech, Inc., Q2 2026 Earnings Call, Aug 12, 2026
05-14	Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Journey Medical Corporation secures contract with third major GPO for Emrosi	RE
04-01	Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Fortress Biotech Unit Closes $205 Million PRV Sale	MT
02-23	Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million	MT
01-13	Fortress Biotech shares hit near two-week low, last down 6.6%	RE
01-13	Fortress Biotech seen surging after FDA approval
01-13	Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo	CI
01-13	Fortress Biotech, Cyprium Say FDA Approved Zycubo for Pediatric Patients of Menkes Disease; Shares Rise Pre-Bell	MT
01-13	US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease	RE

Fortress Biotech, Inc. Stock

Stocks

FBIO

US34960Q3074

Pharmaceuticals

Valuation: Fortress Biotech, Inc.

Chart: Fortress Biotech, Inc.

Latest news: Fortress Biotech, Inc.

Last Transcript: Fortress Biotech, Inc.

Analysts' recommendations: Fortress Biotech, Inc.

Press Releases: Fortress Biotech, Inc.

News in other languages: Fortress Biotech, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Fortress Biotech, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly earnings, Rate of surprise

01/10/25	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101	CI
01/10/25	Fortress Biotech Shares Drop After FDA Letter for CUTX-101 Manufacturing Facility	DJ
01/10/25	Fortress Biotech and Cyprium Therapeutics announce an update on the NDA for CUTX-101	RE
19/03/24	Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target	MT
29/11/23	Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating	MT

09-08	Journey Medical Corporation to Participate in September 2026 Investor Conferences	AQ
09-08	Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-14	Fortress Biotech: Q2 Earnings Snapshot	AQ
08-13	Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	AQ
08-12	Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	AQ

01-13	Fortress Biotech attendu en forte hausse après une approbation de la FDA
29/09/21	MÄRKTE USA/Nur maue Erholung - Belastungsfaktoren bleiben
29/09/21	MÄRKTE USA/Moderate Erholung von Vortagesabsturz
30/09/20	Israël limite les manifestations dans le cadre de mesures sanitaires
30/09/20	France : l'inflation a ralenti à 0,1% sur un an en septembre

1 day	+7.57%
1 week	+3.11%
Current month	+3.65%
1 month	-6.79%
3 months	-25.47%
6 months	-16.74%
Current year	-45.63%

1 week	1.79	2.06
1 month	1.79	2.13
Current year	1.79	4.53
1 year	1.79	4.53
3 years	1.28	4.53
5 years	1.24	53.62
10 years	1.24	91.5

Manager	Title	Age	Since
Lindsay Rosenwald CEO	Chief Executive Officer	71	20/12/2013
Xiao Qin Lu DFI	Director of Finance/CFO	51	22/02/2012
David Jin DFI	Director of Finance/CFO	36	16/08/2022

Director	Title	Age	Since
Jimmie Harvey BRD	Director/Board Member	74	01/12/2008
Lindsay Rosenwald CHM	Chairman	71	20/12/2013
J. Jay Lobell BRD	Director/Board Member	63	01/06/2006

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/1/26 A	David Jin	Free	Chief Financial Officer	1,190	0.0036%
4/1/26 A	David Jin	Free	Chief Financial Officer	2,967	0.0096%
3/18/26 A	Lindsay Rosenwald	Free	Chief Executive Officer	475,424	1.5318%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FORTRESS BIOTECH, INC.	+7.57%	+3.11%	-23.75%	-4.33%	66.37M
ELI LILLY AND COMPANY	+4.28%	+0.07%	+52.75%	+138.78%	1,258B
JOHNSON & JOHNSON	+2.13%	+4.27%	+51.21%	+91.36%	679B
ABBVIE INC.	+0.68%	+1.54%	+33.83%	+112.47%	518B
ROCHE HOLDING AG	-0.16%	+2.71%	+43.99%	+69.63%	390B
MERCK & CO., INC.	+1.38%	+0.27%	+72.42%	+45.30%	367B
NOVARTIS AG	-0.04%	+1.64%	+30.78%	+59.38%	307B
ASTRAZENECA PLC	-0.41%	+2.08%	+7.01%	+39.21%	293B
AMGEN INC.	+1.04%	-0.05%	+45.29%	+76.18%	252B
GILEAD SCIENCES, INC.	+1.46%	-0.59%	+42.48%	+125.82%	210B
Average	+1.89%	+1.26%	+35.60%	+75.38%	427B
Weighted average by Cap.	+1.98%	+1.18%	+45.44%	+96.87%

	2026 *	2027 *
Net sales	78.79M 70.33M 64.72M 58.74M 111M 7.39B 114M 774M 309M 3.95B 296M 289M 12.45B	113M 101M 93.02M 84.42M 160M 10.62B 164M 1.11B 444M 5.68B 425M 416M 17.9B
Net income	88.25M 78.77M 72.48M 65.78M 125M 8.27B 128M 867M 346M 4.43B 331M 324M 13.95B	-37.81M -33.75M -31.06M -28.19M -53.42M -3.54B -54.75M -372M -148M -1.9B -142M -139M -5.98B
Net Debt	-	-